Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom
Recruitment status was: Recruiting
Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation.
Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
- Consumption of Xalatan/Xalacom bottles per year per patient. [ Time Frame: 12 months. ]
- Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease [ Time Frame: 12 months ]
- Characterizing the optimal conditions for proper usage of the Xal-Ease device [ Time Frame: 12 months ]
|Study Start Date:||June 2009|
|Estimated Study Completion Date:||October 2012|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01125306
|Ophthalmology department, Meir Medical Center|
|Kfar-Saba, Israel, 44281|